Prolaris Prostate Cancer Prognostic Test

Is your prostate cancer patient in the “grey zone”? The Prolaris Test can help guide your decisions.

When you want to bring clarity and personalization to your prostate cancer treatment discussions, go beyond risk stratification at biopsy with Prolaris Testing.

Reliable genomic insights can help you have more informed, reassuring conversations with patients.​

The Prolaris Test delivers a personalized risk assessment of a patient’s prostate cancer by combining clinically proven information with traditional diagnostic tools like PSA and Gleason Scoring.

45%

of biopsy and surgical Gleason scores do not match.1

34%

of the time, expert-trained GU pathologists disagree about biopsy Gleason scores.2

plays 'Improving the patient experience through genomics' videolightbox

Improving the patient experience through genomics

The Prolaris Test is the most comprehensive test available3

When it comes to making active surveillance or definitive treatment decisions, selecting the correct biomarker test matters. The Prolaris Test is the only test studied in untreated patients that can identify the MOST patients for active surveillance across all biomarkers.5

The Prolaris Test combines genomic (CCP) and clin-path features. CCP is the gold standard for measuring cancer aggressiveness.3

The Prolaris Test is validated in 10,000 patients across all risk groups.4

The Prolaris Test is two times more prognostic than PSA/Gleason alone9


clinical variables graphic

A comprehensive score to help determine cancer aggressiveness

The Prolaris Test has an independent CCP score that determines cancer aggressiveness and is combined with more traditional clinical pathological features like PSA and Gleason to create the most prognostic test on the market.

Go Beyond Risk Stratification at Biopsy

The Prolaris Test can identify which men may be appropriate for active surveillance and those who are not. With two clinically validated thresholds, the Prolaris Test can also identify which patients should consider actively treating their cancer with one form of treatment, like surgery or radiation, and which patients may benefit from multiple forms of treatment.

Active surveillance

Identify active surveillance (AS) patients at time of biopsy

Because the Prolaris Test was developed and validated on untreated men,5 AS conversations with the untreated patient in front of you are more relevant and informed.5

The Prolaris Test outperforms all other biomarkers in identifying the right patients for active surveillance in both low and intermediate risk populations.5

In the Prolaris Test validation study, NO patient below the AS threshold died of prostate cancer.5

The Prolaris Test best aligns with patients studied in ProtecT, the largest randomized trial of AS or treatment in screen-detected localized prostate cancer.6

Single-modal Treatment

Identify the patients who need definitive treatment and at what intensity

The Prolaris Test shows that those patients who fall below the multi-modal threshold do not benefit from intensifying treatment7

Establishing the multi-modal threshold

The Prolaris Test threshold was developed on approximately 1,500 intermediate and high-risk patients from two separate cohorts.

Validating patients prior to a multi-modal treatment

Patients were separated by those who received single-modal therapy versus those with multiple modes of treatment.

Multi-modal Threshold

Guide the androgen deprivation therapy (ADT) conversation

Multiple groups with ADT variations evaluated for metastasis

The Multi-modal threshold was developed and double-validated across all outcomes to predict the risk of metastasis and determine which patients can appropriately forego ADT.7,8

At or below the multi-modal threshold
(8.8% metastasis risk)

The Prolaris Test gives your patients personalized, shareable guidance and a simple “number-needed-to-treat” value.

Is ADT right for this patient?

View the Prolaris Test report

The Prolaris Test provides clarity

2x the predictive power of PSA and Gleason Scoring combined9

Outperforms all other biomarkers in active surveillance10

Only test developed and validated on untreated men5

Most comprehensive: combines genomic, PSA and Gleason scores9

Goes beyond risk stratification to determine which patients may be appropriate for treatment and the appropriate level of intensity

Personalizes ADT decisions with ARR for every patient

When it comes to finding the best tool to bring clarity, utility and personalization to your prostate cancer treatment discussions, the conversation just got easier.

Prolaris Prostate Cancer Prognostic Test
plays 'Prolaris® identifies which patients are safe for active surveillance (AS)' videolightbox

The Prolaris Test identifies which patients may be appropriate for active surveillance (AS)

plays 'Prolaris empowers clinicians during a cancer consult' videolightbox

The Prolaris Test empowers clinicians during a cancer consult

What to expect with every Prolaris Test

Actionable

Every Prolaris Test provides actionable results to inform more confident prostate cancer treatment decisions.

Affordable

Myriad is committed to providing patients with access to accurate and affordable genetic results through extensive coverage with most insurance plans and financial assistance programs.
Learn more

Accurate

Myriad believes in providing the most accurate and highest quality tests for patients. From hereditary cancer to tumor genomic, our tests are designed to give providers and patients the most accurate answer possible.

Prolaris Test resources

Take the next step with the Prolaris Test

Navigate crucial prostate cancer treatment decisions – with the right answers at the right time.

Download Physician Guide



Hidden Fields










You agree to be contacted with newsletters, marketing or promotional materials and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in any email we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Policy.

Contact Information

References:

  1. Schreiber D, Wong AT, Rineer J, Weedon J, Schwartz D. Prostate biopsy concordance in a large population-based sample: a Surveillance, Epidemiology and End Results study. J. Clin. Path. 2015;68(6):453-457. doi:https://doi.org/10.1136/jclinpath-2014-202767.
  2. Allsbrook WC, Mangold KA, Johnson MH, et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: Urologic pathologists. Hum. Pathol. 2001;32(1):74-80. doi:https://doi.org/10.1053/hupa.2001.21134
  3. Cuzick J, Berney DM, Fisher G, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br. J. Cancer. 2012;106(6):1095-1099. doi:https://doi.org/10.1038/bjc.2012.39.
  4. Lin DW, E. David Crawford, Keane T, et al. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urol. Oncol. 2018;36(6):310.e7-310.e13. doi:https://doi.org/10.1016/j.urolonc.2018.03.011.
  5. Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. NEJM. Published online March 11, 2023. doi:https://doi.org/10.1056/nejmoa2214122.
  6. Tward J, Lenz L, Flake DD, et al. The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation. IJROBP. 2022;113(1):66-76. doi:https://doi.org/10.1016/j.ijrobp.2021.09.034.
  7. Tward JD, Schlomm T, Bardot S, et al. Ability of the combined clinical cell-cycle risk score to identify patients that benefit from multi versus single modality therapy in NCCN intermediate and high-risk prostate cancer. J. Clin. Onc. 2020;38(6_suppl):346-346. doi:https://doi.org/10.1200/jco.2020.38.6_suppl.346.
  8. Hu JC, Tosoian JJ, Qi J, et al. Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate Cancer. JCO Precis. Oncol. 2018;(2):1-15. doi:https://doi.org/10.1200/po.18.00163.
  9. Lenz L, Flake DD, et al. The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation. IJROBP. 2022;113(1):66-76. doi:https://doi.org/10.1016/j.ijrobp.2021.09.034.
  10. Tward JD, Schlomm T, Bardot S, et al. Ability of the combined clinical cell-cycle risk score to identify patients that benefit from multi versus single modality therapy in NCCN intermediate and high-risk prostate cancer. J. Clin. Onc. 2020;38(6_suppl):346-346. doi:https://doi.org/10.1200/jco.2020.38.6_suppl.346.
  11. Lenz L, Flake DD, et al. The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation. IJROBP. 2022;113(1):66-76. doi:https://doi.org/10.1016/j.ijrobp.2021.09.034.
  12. Tward JD, Schlomm T, Bardot S, et al.
    Ability of the combined clinical cell-cycle risk score to identify patients that benefit from multi versus single modality therapy in NCCN intermediate and high-risk prostate cancer. J. Clin. Onc. 2020;38(6_suppl):346-346. doi:https://doi.org/10.1200/jco.2020.38.6_suppl.346.

©2025 Myriad Genetics, Inc. Myriad Genetics, Prolaris and their respective logos, are registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions.

Locations

United States
Europe
Japan